Drug repurposing: Bortezomib in the treatment of PTEN-deficient iCCA

Shi-jia Dai; Tian-yi Jiang; Zhen-gang Yuan

doi:10.1002/ctd2.70004

Clinical and Translational Discovery ›› 2024, Vol. 4 ›› Issue (6) : e70004 DOI: 10.1002/ctd2.70004

COMMENTARY

Drug repurposing: Bortezomib in the treatment of PTEN-deficient iCCA

Author information +

History +

PDF

Cite this article

Download citation ▾

Shi-jia Dai, Tian-yi Jiang, Zhen-gang Yuan. Drug repurposing: Bortezomib in the treatment of PTEN-deficient iCCA. Clinical and Translational Discovery, 2024, 4(6): e70004 DOI:10.1002/ctd2.70004

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	IlyasSI, GoresGJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215-1229.

[2]	KelleyRK, UenoM, YooC, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853-1865.

[3]	OhDo-Y, HeAR, BouattourM, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1):updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694-704.

[4]	JiangT-Yi, FengX-F, FangZ, et al. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer. Cancer Lett. 2021;501:187-199.

[5]	LinY-K, FangZ, JiangT-Yi, et al. Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy. Cancer Lett. 2018;421:161-169.

[6]	JiangT-Yi, ShiY-Y, CuiX-W, et al. PTEN deficiency facilitates exosome secretion and metastasis in cholangiocarcinoma by impairing TFEB-mediated lysosome biogenesis. Gastroenterology. 2023;164(3):424-438.

[7]	JiangT-Yi, PanYu-F, WanZ-H, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. Sci Transl Med. 2020;12(562).

[8]	ZengT-M, JiangT-Yi, YangG, et al. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: an open-label, prospective and single-centre phase II trial. Clin Transl Med. 2024;14(5):e1675.

[9]	KisselevAF. Site-specific proteasome inhibitors. Biomolecules. 2021;12(1).

[10]	VoraPA, PatelR, DharamsiA. Bortezomib-First therapeutic proteasome inhibitor for cancer therapy: a review of patent literature. Recent Pat Anticancer Drug Discov. 2020;15(2):113-131.

[11]	BenitezJA, FinlayD, CastanzaA, et al. PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. Neuro Oncol. 2021;23(7):1072-1086.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.